Icon Plc $ICLR Shares Bought by Quartz Partners LLC

Quartz Partners LLC grew its position in shares of Icon Plc (NASDAQ:ICLR) by 47.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,620 shares of the medical research company’s stock after purchasing an additional 8,516 shares during the quarter. Quartz Partners LLC’s holdings in Icon were worth $2,946,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in ICLR. Toth Financial Advisory Corp acquired a new stake in shares of Icon in the 4th quarter valued at about $27,000. EFG International AG purchased a new position in Icon during the 4th quarter worth approximately $27,000. Abound Financial LLC acquired a new position in Icon during the fourth quarter worth approximately $54,000. Johnson Financial Group Inc. purchased a new stake in Icon in the third quarter valued at approximately $71,000. Finally, Blue Trust Inc. lifted its stake in Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after buying an additional 444 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ICLR. Bank of America raised their target price on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research report on Thursday, June 25th. Truist Financial upgraded shares of Icon from a “hold” rating to a “buy” rating and upped their price target for the company from $159.00 to $207.00 in a research report on Tuesday, June 30th. DA Davidson set a $164.00 price target on shares of Icon in a research note on Monday, June 1st. Robert W. Baird raised their price objective on shares of Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, TD Cowen lifted their price objective on shares of Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Nine investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $173.19.

Icon Trading Down 1.2%

Shares of ICLR stock opened at $170.00 on Friday. The company has a market capitalization of $13.02 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 8.45 and a beta of 1.22. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $145.31 and its two-hundred day moving average is $136.78. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00.

Icon (NASDAQ:ICLR) last released its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.43 by $0.07. Icon had a return on equity of 8.73% and a net margin of 5.35%.The business had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the business earned $3.43 earnings per share. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts forecast that Icon Plc will post 9.43 EPS for the current year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.